Based on 24 Wall Street analysts offering 12 month price targets for Biogen in the last 3 months. The average price target is $287.27 with a high forecast of $350.00 and a low forecast of $200.00. The average price target represents a 24.88% change from the last price of $230.04.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"199":"$199","237":"$237","275":"$275","313":"$313","351":"$351"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":350,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$350.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":287.27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$287.27</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$200.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[199,237,275,313,351],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2023","6":"Nov<br/>2023","9":"Feb<br/>2024","12":"May<br/>2024","25":"May<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,217.51,227.70153846153846,237.8930769230769,248.08461538461538,258.2761538461538,268.4676923076923,278.65923076923076,288.85076923076923,299.0423076923077,309.2338461538461,319.4253846153846,329.61692307692306,339.80846153846153,{"y":350,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,217.51,222.87615384615384,228.2423076923077,233.60846153846154,238.97461538461536,244.3407692307692,249.70692307692306,255.0730769230769,260.43923076923073,265.8053846153846,271.17153846153843,276.5376923076923,281.90384615384613,{"y":287.27,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,217.51,216.16307692307691,214.81615384615384,213.46923076923076,212.1223076923077,210.7753846153846,209.42846153846153,208.08153846153846,206.73461538461538,205.3876923076923,204.04076923076923,202.69384615384615,201.34692307692308,{"y":200,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":309.6,"date":1683849600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":300.2,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":275.07,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":268.92,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":267.17,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":263.25,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":249.5,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":234.64,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":257.88,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":243.72,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":220.95,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":203.87,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":217.51,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$350.00

Average Price Target$287.27

Lowest Price Target$200.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

xxxxxxxxxxxxxxxxxx

Truist Financial

xxxxxxxxxxxxx

Reiterated

05/16/24

xxxxxxxxxxxxxxxxxx

Barclays

xxxxxxxxxxxxx

Reiterated

05/16/24

xxxxxxxxxxxxxxxxxx

Jefferies

xxxxxxxxxxxxx

Assigned

05/15/24

xxxxxxxxxxxxxxxxxx

HSBC

xxxxxxxxxxxxx

Reiterated

05/03/24

xxxxxxxxxxxxxxxxxx

Oppenheimer

xxxxxxxxxxxxx

Reiterated

04/29/24

xxxxxxxxxxxxxxxxxx

H.C. Wainwright

xxxxxxxxxxxxx

Assigned

04/25/24

xxxxxxxxxxxxxxxxxx

Morgan Stanley

xxxxxxxxxxxxx

Reiterated

04/25/24

xxxxxxxxxxxxxxxxxx

Scotiabank

xxxxxxxxxxxxx

Reiterated

04/25/24

xxxxxxxxxxxxxxxxxx

Wedbush

xxxxxxxxxxxxx

Reiterated

04/25/24

xxxxxxxxxxxxxxxxxx

Robert W. Baird

xxxxxxxxxxxxx

Reiterated

04/25/24

Salveen Richter

Goldman Sachs

$340.00

Buy

47.80%

Upside

Assigned

04/24/24

Biogen (BIIB) PT Lowered to $340 at Goldman SachsGoldman Sachs analyst Salveen Richter lowered the price target on Biogen (NASDAQ: BIIB) to $340.00 (from $393.00) while maintaining a Buy rating.

Brian Abrahams

RBC Capital

$317.00

Buy

37.80%

Upside

Reiterated

04/24/24

Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB), Evolent Health (NYSE: EVH) and BioMarin Pharmaceutical (NASDAQ: BMRN)

Mohit Bansal

Wells Fargo

$240.00

Hold

4.33%

Upside

Reiterated

04/24/24

Analysts Offer Insights on Healthcare Companies: Thermo Fisher (NYSE: TMO), Biogen (NASDAQ: BIIB) and Molina Healthcare (NYSE: MOH)

Phil Nadeau

TD Cowen

$300.00

Buy

30.41%

Upside

Reiterated

04/24/24

Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB), Dexcom (NASDAQ: DXCM) and Herbalife (NYSE: HLF)

Geoff Meacham

Bank of America Securities

$250.00

Hold

8.68%

Upside

Reiterated

04/24/24

Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (NASDAQ: DAWN), Biogen (NASDAQ: BIIB) and Neurocrine (NASDAQ: NBIX)

Best Analysts Covering Biogen

Which Analyst Should I Follow If I Want to Buy BIIB and Sell After:

1 Month

Salim SyedMizuho Securities

Success Rate

14/29 ratings generated profit

Average Return

+1.22%

assigned a buy rating 23 days ago

Copying Salim Syed's trades and holding each position for 1 Month would result in 48.28% of your transactions generating a profit, with an average return of +1.22% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

3 Months

Brian AbrahamsRBC Capital

Success Rate

13/21 ratings generated profit

Average Return

+4.11%

reiterated a buy rating 23 days ago

Copying Brian Abrahams's trades and holding each position for 3 Months would result in 61.90% of your transactions generating a profit, with an average return of +4.11% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

1 Year

Brian AbrahamsRBC Capital

Success Rate

10/21 ratings generated profit

Average Return

+4.40%

reiterated a buy rating 23 days ago

Copying Brian Abrahams's trades and holding each position for 1 Year would result in 47.62% of your transactions generating a profit, with an average return of +4.40% per trade.

2 Years

Michael YeeJefferies

Success Rate

17/39 ratings generated profit

Average Return

-1.39%

assigned a buy rating 2 days ago

Copying Michael Yee's trades and holding each position for 2 Years would result in 43.59% of your transactions generating a profit, with an average return of -1.39% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BIIB Analyst Recommendation Trends

Rating

Jan 24

Feb 24

Mar 24

Apr 24

May 24

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BIIB has received 33 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. BIIB average Analyst price target in the past 3 months is $287.27.

Each month's total comprises the sum of three months' worth of ratings.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxxxxxxxxxxxxxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

BIIB Financial Forecast

BIIB Earnings Forecast

Next quarter’s earnings estimate for BIIB is $3.98 with a range of $3.40 to $6.04. The previous quarter’s EPS was $3.67. BIIB beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.22% of the time in the same period. In the last calendar year BIIB has Outperformed its overall industry.

BIIB Sales Forecast

Next quarter’s sales forecast for BIIB is $2.38B with a range of $2.32B to $2.45B. The previous quarter’s sales results were $2.20B. BIIB beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 46.20% of the time in the same period. In the last calendar year BIIB has Underperformed its overall industry.

BIIB Stock Forecast FAQ

What is BIIB’s average 12-month price target, according to analysts?

Based on analyst ratings, Biogen’s 12-month average price target is $287.27.

What is BIIB’s upside potential, based on the analysts’ average price target?

Biogen has 24.88% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BIIB a Buy, Sell or Hold?

Biogen has a conensus rating of Strong Buy which is based on 18 buy ratings, 6 hold ratings and 0 sell ratings.

What is Biogen’s price target?

The average price target for Biogen is $287.27. This is based on 24 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $350.00 ,the lowest forecast is $200.00. The average price target represents 24.88% Increase from the current price of $230.04.

What do analysts say about Biogen?

Biogen’s analyst rating consensus is a Strong Buy. This is based on the ratings of 24 Wall Streets Analysts.

How can I buy shares of BIIB?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Biogen (BIIB) Stock Forecast & Price Target

BIIB Analyst Ratings

BIIB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Biogen

BIIB Analyst Recommendation Trends

BIIB Financial Forecast

BIIB Earnings Forecast

BIIB Sales Forecast

BIIB Stock Forecast FAQ

Get More with TipRanks Premium

Detailed List of Analyst Forecasts